|
War da nicht eine KE!!!!!!
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20151217
DATE AS OF CHANGE: 20151217
December 9, 2015
(Date of Event Which Requires Filing of this Statement)
Percent of class:
Sabby Healthcare Master Fund, Ltd. - 5.04%
Sabby Volatility Warrant Master Fund, Ltd. - 2.02%
Sabby Management, LLC - 7.05%
Hal Mintz - 7.05%
http://www.sec.gov/Archives/edgar/data/1113423/...35610-15-000077.txt
http://www.sec.gov/Archives/edgar/data/1113423/...35610-16-000136.txt
The DSMB's decision followed completion of its pre-specified final interim analysis on efficacy and safety at approximately 192 events. The ZoptEC study will conclude upon the occurrence of approximately 384 events, which we expect to occur by September 2016. After the conclusion of the study, the data obtained will be analyzed and we will make a decision regarding the likelihood that the FDA will approve the compound for its indication. If we conclude that there is a reasonable likelihood of approval, we will prepare and file a New Drug Application ("NDA") seeking approval of the compound for its indication. The FDA typically requires one year to make a decision on the approvability of an NDA.
http://secfilings.nasdaq.com/...A&RcvdDate=1%2F12%2F2016&pdf=
BESTÄTIGT sind:
6,9 Mio AEternas
0,445 Mio Warrants Serie-A
8,1 T Serie-B Warrants
Both the Series A and Series B warrants are subject to certain anti-dilution provisions
The Offering was completed on December 14, 2015. Prior to closing, the underwriter exercised its over-allotment option with respect to the warrants to acquire an additional 231,000 common shares, resulting in the issuance by the Corporation, at closing, of 3.0 million common shares and warrants to acquire an aggregate of 2,331,000 common shares, generating net proceeds of approximately US$15.0 million.
http://secfilings.nasdaq.com/...&RcvdDate=12%2F15%2F2015&pdf=
Investors whose purchase of common shares in the Offering would result in them beneficially owning more than the initial beneficial ownership limitation to be included in the warrants following the consummation of the Offering will have the opportunity to acquire pre-funded warrants substituted for any common shares they would have otherwise acquired over the initial beneficial ownership limitation, paying the same price per share
http://secfilings.nasdaq.com/...K&RcvdDate=12%2F9%2F2015&pdf=
Dann rechne mal!
|
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 25 | 17.118 | Aeterna nach dem Split | Heron | Mercy | 02.05.25 19:18 | |
| 9 | 13.769 | AEZS vs. KERX | Gropius | paioneer | 03.09.22 18:22 | |
| 19 | Wie geht's jetzt weiter mit Aeterna Zentaris? | Ebi52 | Bullish_Hope | 03.08.22 00:11 | ||
| 21 | 7.680 | Aeterna Zentaris Inc. | Heron | Heron | 30.09.21 23:37 | |
| 2 | 62 | AEterna Zentaris (AEZS)- Reboundkandidat?? | Vollzeittrader | marroni | 25.04.21 13:13 |